News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|March 31, 2011

Featured Supplement

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Pediatric clinical trial update: June 2026

Pediatric clinical trial update: June 2026

ByMorgan Ebert, Executive Editor

June 30th 2026

Blur image of medical clinic | Image Credit: © whyframeshot - stock.adobe.com

Navepegritide's bone-alignment effects hold through 2 years

ByBenjamin P. Saylor

June 30th 2026

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

ByMorgan Ebert, Executive Editor

June 29th 2026

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression | Image credit: © New Africa - stock.adobe.com

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression

ByMorgan Ebert, Executive Editor

June 29th 2026

Pediatric clinical trial update: Q2 2026

Pediatric clinical trial update: Q2 2026

ByMorgan Ebert, Executive Editor

June 29th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

AAP updates guidance on pediatric iron deficiency screening and treatment

Pediatric clinical trial update: Q2 2026

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression